- Home
- FE vs BDTX Comparison
FE vs BDTX Comparison
Compare FE & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FE | BDTX |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2B | 104.0M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FE | BDTX |
|---|---|---|
| Price | $46.83 | $1.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $50.71 | $10.86 |
| AVG Volume (30 Days) | ★ 4.5M | 856.9K |
| Earning Date | 10-27-2026 | 11-24-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | 3.53 | ★ 130.71 |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $15,090,000,000.00 | N/A |
| Revenue This Year | $6.65 | N/A |
| Revenue Next Year | $5.63 | N/A |
| P/E Ratio | $66.46 | ★ N/A |
| Revenue Growth | ★ 12.01 | N/A |
| 52 Week Low | $42.67 | $1.53 |
| 52 Week High | $52.34 | $4.20 |
Technical Indicators
Market Signals| Indicator | FE | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 39.34 |
| Support Level | $46.71 | N/A |
| Resistance Level | $47.69 | $1.94 |
| Average True Range (ATR) | 0.73 | 0.15 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 53.33 | 11.46 |
Price Performance
Historical ComparisonAbout FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with operations across five mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.